Finnish (OMX) Pharma Industry Analysis

Industry Valuation and Performance

Has the Finnish Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sat, 25 Jul 2026	€11.1b	€2.1b	€587.1m	18.8x	18.8x	5.4x
Mon, 22 Jun 2026	€9.5b	€2.0b	€529.4m	17.9x	17.9x	4.9x
Wed, 20 May 2026	€10.0b	€2.0b	€529.4m	19x	19x	5.1x
Fri, 17 Apr 2026	€10.4b	€1.9b	€500.3m	20.7x	20.7x	5.5x
Sun, 15 Mar 2026	€9.8b	€1.9b	€500.3m	19.5x	19.5x	5.2x
Tue, 10 Feb 2026	€10.5b	€1.6b	€307.7m	33.4x	34.1x	6.4x
Thu, 08 Jan 2026	€9.3b	€1.6b	€307.7m	29.7x	30.4x	5.7x
Sat, 06 Dec 2025	€8.6b	€1.6b	€307.7m	27.3x	27.9x	5.3x
Mon, 03 Nov 2025	€8.6b	€1.6b	€307.7m	27.2x	27.9x	5.3x
Wed, 01 Oct 2025	€9.2b	€1.7b	€372.5m	24.2x	24.7x	5.5x
Fri, 29 Aug 2025	€9.7b	€1.7b	€372.5m	25.5x	25.9x	5.8x
Sun, 27 Jul 2025	€9.9b	€1.7b	€378.0m	26.3x	26.2x	5.9x
Tue, 24 Jun 2025	€9.0b	€1.6b	€347.4m	25.9x	25.9x	5.7x
Thu, 22 May 2025	€8.4b	€1.6b	€347.4m	24.2x	24.2x	5.3x
Sat, 19 Apr 2025	€6.9b	€1.5b	€329.9m	20.9x	20.9x	4.5x
Mon, 17 Mar 2025	€7.8b	€1.5b	€329.9m	23.7x	23.6x	5x
Wed, 12 Feb 2025	€7.3b	€1.4b	€331.1m	22x	22.1x	5.1x
Fri, 10 Jan 2025	€6.3b	€1.4b	€331.1m	19x	19.1x	4.4x
Sun, 08 Dec 2024	€6.3b	€1.4b	€331.1m	19.1x	19.2x	4.4x
Tue, 05 Nov 2024	€6.4b	€1.4b	€331.1m	19.1x	19.2x	4.5x
Thu, 03 Oct 2024	€6.9b	€1.3b	€231.7m	29.6x	29.8x	5.5x
Sat, 31 Aug 2024	€6.8b	€1.3b	€231.7m	29x	29.2x	5.4x
Mon, 29 Jul 2024	€5.8b	€1.2b	€217.1m	68.7x	26.8x	4.8x
Wed, 26 Jun 2024	€5.6b	€1.2b	€217.1m	72x	25.9x	4.6x
Fri, 24 May 2024	€5.3b	€1.2b	€217.1m	63.3x	24.5x	4.4x
Sun, 21 Apr 2024	€4.6b	€1.2b	€217.1m	62.2x	21.1x	3.9x
Tue, 19 Mar 2024	€5.0b	€1.2b	€217.1m	61.8x	23x	4.2x
Thu, 15 Feb 2024	€5.6b	€1.2b	€216.8m	25.6x	25.7x	4.7x
Sat, 13 Jan 2024	€6.0b	€1.2b	€173.2m	34.6x	34.6x	5.2x
Mon, 11 Dec 2023	€5.1b	€1.2b	€173.2m	29.7x	29.6x	4.4x
Wed, 08 Nov 2023	€5.2b	€1.2b	€173.2m	30.1x	30.1x	4.5x
Fri, 06 Oct 2023	€5.2b	€1.4b	€306.3m	17.5x	17x	3.9x
Sun, 03 Sep 2023	€5.4b	€1.4b	€306.3m	17.5x	17.5x	4x
Tue, 01 Aug 2023	€4.9b	€1.4b	€306.3m	16x	16.1x	3.6x

Current Industry PE

There is only one company in the Finnish Pharmaceuticals industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have grown 24% per year over the last three years.
Revenues for these companies have grown 15% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Finnish Healthcare industry?


FI Market	-0.16%
Healthcare	0.45%
Pharma	1.36%
Pharma	1.36%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

	Company	Last Price	7D	1Y	Valuation
	ORNBV Orion Oyj	€78.45	1.4% +€147.9m	11.2%	PE18.8x

Company

Last Price

Valuation

ORNBV Orion Oyj

€78.45

1.4%
+€147.9m

11.2%

PE18.8x

Herantis Pharma Finalizes Phase 2a Study Design For HER-096 And Reports Positive FDA Feedback

Herantis Pharma recently completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned clinical development of HER-096. The FDA raised no concerns regarding the Company's chemistry, manufacturing and controls (CMC) information or preclinical data package and confirmed that, based on the current data package, Herantis would be in a position to activate U.S. clinical sites should an Investigational New Drug (IND) application be submitted. The FDA considered the Phase 2a trial design appropriate for the current stage of development and discussions also included the endpoint strategy for future clinical studies. The Phase 2a study is designed to evaluate the efficacy, safety and tolerability of HER-096 in patients with early-stage Parkinson's disease and is expected to provide the first evidence of its potential to deliver meaningful clinical benefit in patients. The randomized, double-blind, placebo-controlled study is expected to enroll approximately 100 newly diagnosed Parkinson’s disease patients who are not receiving symptomatic medication across multiple sites in Europe. Patients will receive twice-weekly subcutaneous dosing of HER-096 or placebo for six months, followed by a six-month open-label extension. The study will use a Digital Motor Score (DMS) as its primary endpoint, complemented by established clinical assessments, imaging and biomarker analyses. The integration of Indivi's digital biomarker platform is intended to provide objective and continuous assessments of disease progression and treatment response. Herantis has appointed CTC Clinical Trial Consultants AB (CTC) as the clinical CRO to support the execution of the Phase 2a study. CTC brings extensive experience in Parkinson's disease clinical trials and will support study start-up, site management and operational execution across participating study centers. Herantis has already secured significant support for the program through the previously announced EUR 8 million Horizon Europe grant and the potential for further investment from the European Innovation Council (EIC) Fund. Over 50% of the funding required to execute the Phase 2 study has been secured or identified. The Company continues to evaluate financing alternatives to support advancement into Phase 2, including strategic partnerships, equity financing and non-dilutive funding. HER-096 is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER-096 was shown to be generally safe and well tolerated in Parkinson’s disease patients.

Finnish (OMX) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Orion Oyj (HEL:ORNBV) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Herantis Pharma Finalizes Phase 2a Study Design For HER-096 And Reports Positive FDA Feedback